3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation

A technology for dihydrotetrabenazine and proliferative diseases, which is applied in the directions of bone diseases, anti-inflammatory agents, organic active ingredients, etc., and can solve the problems of undisclosed therapeutic uses and the like

Inactive Publication Date: 2008-12-10
BIOVAIL LAB INT BARBADOS
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

PCT / GB2005 / 00464 contains experimental data showing that the cis-dihydrotetrabenazine isomer binds to sigma-1 and sigma-2 receptors, but does not disclose any therapeutic use using sigma receptor binding activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
  • 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
  • 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0201] Preparation of 2S, 3S, 11bR and 2R, 3R, 11bS Isomers of Dihydrotetrabenazine 1A. Reduced RR / SS Tetrabenazine

[0202]

[0203] 1M L-Selectride in tetrahydrofuran (135ml, 135mmol, 2.87eq) was dissolved at 0°C over 30 minutes To a stirred solution of tetrabenazine RR / SS racemate (15 g, 47 mmol) in ethanol (75 ml) and tetrahydrofuran (75 ml) was added slowly. The mixture was stirred at 0 °C for 30 min after complete addition and then allowed to warm to room temperature.

[0204] The mixture was poured onto crushed ice (300g) and water (100ml) was added. The solution was extracted with diethyl ether (2 x 200ml) and the combined ethereal extracts were washed with water (100ml) and partially dried over anhydrous potassium carbonate. Drying was completed with anhydrous magnesium sulfate, and after filtration, the solvent was removed under reduced pressure (protected from light, bath temperature <20°C) to obtain a pale yellow solid.

[0205] The solid was slurried wi...

Embodiment 2

[0233] Preparation of 2R, 3S, 11bR and 2S, 3R, 11bS Isomers of Dihydrotetrabenazine

[0234] 2A. Preparation of 2,3-dihydrotetrabenazine

[0235] According to the method of embodiment 1A, use L-Selectride Reduction of a THF solution containing a racemic mixture of RR and SS tetrabenazine enantiomers (15 g, 47 mmol) afforded a mixture of 2S, 3R, 11bR and 2R, 3S, 11bS enantiomers of dihydrotetrabenazine (12 g , 80%), as a white powdery solid. Then according to the method of embodiment 1B, with PCl 5 Dehydration of the partially purified dihydrotetrabenazine afforded a semi-purified mixture of the 11bR and 11bS isomers of 2,3-dihydrotetrabenazine (the 11bR enantiomers are not shown below) (12.92 g, 68% ), as a yellow solid.

[0236]

[0237] 2B. Epoxidation of the Crude Olefin from Example 2A

[0238]

[0239] A solution of 70% perchloric acid (3.70ml, 43mmol) in methanol (215ml) was added to a stirred solution of the crude olefin from Example 2A (12.92g, 42.9mmo...

Embodiment 3

[0271] Alternative Methods for the Preparation of Isomer B and the Preparation of the Mesylate Salt

[0272] 3A. Reduced RR / SS Tetrabenazine

[0273]

[0274] 1M Selectride in tetrahydrofuran (52ml, 52mmol, 1.1 equivalents) was added in 30 minutes To a cooled (ice bath), stirred solution of tetrabenazine racemate (15 g, 47 mmol) in tetrahydrofuran (56 ml) was added slowly. After the addition was complete, the mixture was allowed to warm to room temperature and stirred for an additional 6 hours. TLC analysis (silica, ethyl acetate) showed very little starting material remaining.

[0275] The mixture was poured into a stirred mixture of crushed ice (112g), water (56ml) and glacial acetic acid (12.2g). The resulting yellow solution was washed with diethyl ether (2 x 50ml) and basified by the slow addition of solid sodium carbonate (ca. 13g). Pet-ether (30-40°C) (56ml) was added to the mixture with stirring and the crude product β-DHTBZ was collected by filtration as a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,1lb-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof.

Description

[0001] The present invention relates to the use of dihydrotetrabenazine in medicines for preventing or treating inflammatory diseases and cancers. Background of the invention [0002] Cancer is a collective term given to a class of diseases characterized by abnormal and uncontrolled cell growth. Normally, cells grow and divide to form new cells only when the body needs them. When cells age and die, new cells take their place. Genetic mutations in cells can sometimes disrupt this process, so that new cells form when the body doesn't need them, but old cells that should die don't. This extra cell forms a mass of tissue called a growth, neoplasm, or tumor. Tumors can be either benign (noncancerous) or malignant (cancerous). Benign tumors do not spread to other parts of the body, so they are rarely life-threatening, whereas malignant tumors can spread (metastasize), and thus can be life-threatening. Cancers arise within a single cell and can thus be classified according to the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/473A61P29/00A61P19/02A61P35/00
CPCA61K31/473A61P1/00A61P1/04A61P19/00A61P19/02A61P19/06A61P29/00A61P35/00A61P43/00
Inventor A·J·杜菲尔德
Owner BIOVAIL LAB INT BARBADOS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap